Wegovy and Pregnancy: Is Semaglutide Safe? The 2-Month Washout Rule

The short, careful answer: Wegovy (semaglutide) is not something you should be taking for weight loss while pregnant, and the FDA label instructs clinicians to discontinue Wegovy in pregnant patients who are using it for weight reduction once a pregnancy is recognized.^[1] Because semaglutide has a long half-life of about one week, the label also advises stopping it at least 2 months before a planned pregnancy, so it has cleared your system before you conceive.^[1] Wegovy now comes in two forms — the original once-weekly injection and, since early 2026, a once-daily 25 mg tablet — and while the pregnancy guidance is the same for both, the breastfeeding guidance is not: the tablet label specifically advises against breastfeeding while the injection label does not carry that same blanket caution. This article explains exactly what the current Wegovy label says, the reasoning behind the 2-month washout, what to do if you conceived while taking it, the injection-vs-tablet breastfeeding distinction, and the fertility/PCOS context behind "GLP-1 babies" headlines. It is general education, not medical advice — pregnancy decisions belong with your OB-GYN or endocrinologist. See our Wegovy drug page and our companion Ozempic and pregnancy article (same molecule, the type-2-diabetes brand) for the broader picture.

What the FDA Wegovy label actually says

Wegovy's label addresses pregnancy in §8.1. The Risk Summary states plainly: "Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy."^[1] On what to do if pregnancy occurs, the label's instruction is specific to the weight-management use: "When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY in pregnant patients who are using it for weight reduction."^[1]

That "for weight reduction" qualifier is worth pausing on — it is there because, since August 2025, Wegovy also carries a separate FDA indication for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis, and the label handles that indication differently in pregnancy, weighing benefit against risk case-by-case rather than issuing a blanket discontinue instruction.^[1] For the overwhelming majority of readers on this page — using Wegovy for weight management — the relevant instruction is the direct one: weight loss offers no benefit during pregnancy, so there is no competing reason to stay on it, and the label's guidance is to stop.

This differs slightly in framing from Ozempic's label (the type-2-diabetes brand of the same molecule, semaglutide), which has to account for the fact that poorly controlled diabetes carries its own pregnancy risks. Wegovy's weight-management use has no equivalent competing concern — intentional weight loss is not a treatment goal during pregnancy — so the label's position for Wegovy specifically is more categorical.

The 2-month washout before a planned pregnancy

If you are planning a pregnancy, the label gives a concrete timing rule, quoted verbatim: "discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide."^[1] This is the most actionable, frequently-searched fact in this whole topic — the so-called "2-month rule" — and it applies to both the Wegovy injection and the Wegovy tablet, since both deliver the same active ingredient.

The reasoning is pharmacokinetic. A drug's half-life is the time it takes for the amount in your body to fall by half, and as a rule of thumb a drug is largely cleared after roughly four to five half-lives. With semaglutide's ~1-week half-life, that places near-complete clearance in the neighborhood of 5 weeks or so — and the label's ~2-month buffer adds a deliberate margin of safety on top, so that by the time you are trying to conceive (and through the earliest, most vulnerable weeks of fetal development, which can begin before a pregnancy is even detected) there is essentially no semaglutide on board.^[1] In practical terms: if you and your clinician decide you want to try to conceive, the plan is to stop Wegovy about two months ahead of starting to try, with a reliable contraception plan in place until then.

This timing is something to map out with your OB-GYN or endocrinologist, who can fold in your weight history, any other medications, and — since Wegovy's whole purpose is weight management — how you plan to approach the weight trajectory during the washout itself (more on that below).

Why — animal reproductive-toxicity findings and limited human data

The caution rests on two facts that pull in the same direction: the human data are limited, and the available animal data are concerning.

On the human side, there is not enough data from pregnant patients to establish whether semaglutide is associated with major birth defects, miscarriage, or adverse maternal or fetal outcomes. A 2026 systematic review and meta-analysis of neonatal and obstetric outcomes after periconceptional GLP-1 exposure found no clear signal of elevated major-malformation risk above background, but the authors are explicit that the pooled studies are not powered to rule out smaller effects.^[3] A companion 2026 systematic safety review across preconception, pregnancy, and lactation reached the same directionally reassuring, still-cautious conclusion.^[4] "Reassuring but limited" is not the same as "cleared" — and in pregnancy, an unanswered safety question defaults to caution.

On the animal side, the Wegovy label reports, quoted verbatim: "In pregnant rats administered semaglutide during organogenesis, embryofetal mortality, structural abnormalities and alterations to growth occurred at clinically relevant maternal exposures."^[1] Animal findings do not automatically translate to humans, but in the absence of definitive human data they carry real weight in how regulators and clinicians reason about risk. A 2025 clinical review of GLP-1 receptor agonist use in pregnancy summarizes this exact rationale as the basis for the class-wide labeling and the 2-month preconception window.^[2] Together, "limited human data plus adverse animal reproductive findings" is precisely the combination that produces Wegovy's discontinuation instruction and the 2-month washout advice above.

If you conceived while taking Wegovy

First, the reassuring framing: discovering you are pregnant while on Wegovy is not, by itself, a reason to panic, and it is a situation clinicians see and manage. The "limited data" status above cuts both ways — it means harm has not been demonstrated either. What it does mean is that you should act, and act through your clinician.

The labeled guidance is direct: once pregnancy is recognized, discontinue Wegovy and the patient should be advised of the potential risk.^[1] The 2025 clinical review of GLP-1 use in pregnancy is explicit that standard obstetric practice for an inadvertent exposure is to stop the drug, refer to maternal-fetal medicine if indicated, and continue routine prenatal care — inadvertent first-trimester exposure is not, on its own, an indication for terminating a pregnancy.^[2] Practically, that means:

• Stop Wegovy and contact your OB-GYN (and your prescriber) promptly. Don't wait for the next scheduled dose; reach out so the next steps can be planned.
• Don't assume harm — and don't make any irreversible decision based on the medication alone. The human data are reassuring in the aggregate but limited; your OB-GYN is the right person to discuss what this means for your individual pregnancy, including any monitoring they recommend.^[3][4]
• Ask about reporting to a pregnancy registry / surveillance. Manufacturer and regulatory pharmacovigilance programs collect outcomes data on medication exposures in pregnancy; your clinician can advise whether and how to report, which also helps close the very data gap that drives the uncertainty here.^[2]

The single most useful sentence to carry away: stop it, and call your provider — not as an emergency-room dash, but as a prompt, deliberate step so a clinician who knows your history can guide the rest.

Breastfeeding on Wegovy — the injection is not the tablet

This is the piece of the Wegovy label most likely to be conflated with Ozempic's, and it is important to get right: the Wegovy injection and the Wegovy tablet have different lactation guidance, because they are formulated differently.

For the Wegovy injection (the original once-weekly subcutaneous pen), the label states there are no data on the presence of subcutaneously administered semaglutide or its metabolites in human milk, and frames the decision the way most GLP-1 injectable labels do — "the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for WEGOVY and any potential adverse effects on the breastfed child."^[1] In other words, the injection label does not broadly advise against breastfeeding — it frames it as an individualized, clinician-guided decision, the same posture Ozempic's label takes.

For the Wegovy tablet (the once-daily 25 mg oral formulation launched in early 2026), the label is more direct: it specifically advises that breastfeeding is not recommended during treatment with WEGOVY tablets.^[1] The reason is formulation-specific, not a semaglutide effect: the tablet uses an absorption-enhancing excipient (salcaprozate sodium, or SNAC) to let the peptide survive digestion and cross into the bloodstream, and SNAC itself is a small molecule that can pass into human milk in ways the injection's formulation does not.^[1]

The practical takeaway: "can I breastfeed on Wegovy" does not have one universal answer — it depends on which Wegovy. If you are on the injection and breastfeeding, raise it with your clinician as an individualized risk/benefit conversation. If you are on the tablet, the label's position is a direct caution against breastfeeding during treatment. Either way, this is a conversation for your OB-GYN, pediatrician, or endocrinologist before starting or restarting Wegovy in any formulation while breastfeeding.

Fertility, PCOS, and the "GLP-1 babies" context

You have likely seen headlines about so-called "Ozempic babies" or "GLP-1 babies" — reports of unexpected pregnancies in people taking GLP-1 medications, Wegovy included. It is worth being precise about what is and isn't being claimed here, because it is easy to overread.

There are two plausible, non-mysterious mechanisms behind the phenomenon, and neither makes Wegovy a fertility treatment — it is not FDA-approved to treat infertility:

• Weight loss can restore ovulation, especially in PCOS. In polycystic ovary syndrome (PCOS) and in obesity-related anovulation, meaningful weight loss can improve insulin resistance and help restore more regular ovulation and menstrual cycles — which can improve fertility. A small pilot study of pre-conception liraglutide (a related but different GLP-1) added to metformin improved IVF pregnancy rates in obese PCOS patients who had a poor response to first-line treatment, versus metformin alone, despite similar weight loss between groups — suggesting effects beyond weight loss alone, though the trial was small (n=28) and not semaglutide-specific.^[7] A separate case series reported restored ovulatory cycles in obese PCOS patients treated with semaglutide directly.^[5] This is a downstream effect of weight loss (and possibly other mechanisms), not a direct fertility action Wegovy is approved for.
• Reduced birth-control effectiveness. The other contributor is unintended pregnancy from contraception failing — covered in the next section — particularly with oral contraceptives around the GI upset these drugs can cause. An "unexpected" pregnancy can simply be a pill that didn't work as expected.

The practical implication runs the opposite direction from the headlines: if you are taking Wegovy and do not want to become pregnant, you should be more attentive to reliable contraception, not less — because your fertility may have quietly improved even as the drug itself must be stopped before pregnancy. If you are trying to conceive, the plan is to come off Wegovy (with the ~2-month washout) and pursue fertility care through the appropriate clinician, not to rely on the medication itself.

Birth control and Wegovy

Because Wegovy is avoided in pregnancy and may coincide with improved fertility, effective contraception matters more, not less, while you are on it. Semaglutide (the Wegovy/Ozempic molecule) does not carry the same FDA-labeled oral-contraceptive interaction warning that tirzepatide (Mounjaro/Zepbound) does — that warning is specific to tirzepatide's larger effect on gastric emptying.^[6] That said, one general GI caution still applies to any oral medication taken alongside Wegovy: vomiting or significant diarrhea — both possible during Wegovy dose increases — can reduce how much of an oral contraceptive your body absorbs, theoretically lowering its protection. This is a general principle for pairing any oral medication with a drug that can cause GI upset, not a Wegovy-specific labeled warning.

The point for this article is narrow and important: if avoiding pregnancy is your goal while on Wegovy, confirm your contraception plan with your provider, especially across the weeks when GI side effects are heaviest — and remember that some clinicians favor a non-oral, highly reliable method (an IUD, implant, or other long-acting reversible contraception) specifically because it doesn't depend on gastrointestinal absorption at all.

The weight-regain question during the washout

Because Wegovy exists specifically for weight management, one question the Ozempic version of this topic doesn't have to address as directly is: what happens to your weight during the 2-month washout, and after? The STEP-4 randomized trial randomized patients who had reached steady-state weight loss on semaglutide 2.4 mg to either continue the drug or switch to placebo for another 48 weeks; the continue group lost a further ~7.9% of body weight, while the placebo group regained ~6.9%.^[8] Weight regain after stopping a GLP-1 typically begins within weeks of the last dose, not months. The practical implication for preconception planning: your on-drug weight is not a stable baseline you'll hold through the washout and into early pregnancy — expect some upward drift, and talk to your OB-GYN about nutrition and activity planning for that window rather than assuming the pre-washout number will hold.

Key guidance at a glance

Bottom line — plan with your clinician

• Wegovy (semaglutide) is not recommended for pregnant patients using it for weight loss. If you become pregnant, the label says to discontinue it and contact your provider.^[1]
• Planning a pregnancy? Stop it at least ~2 months ahead. Semaglutide's ~1-week half-life means it needs roughly two months, with a safety margin, to clear before you try to conceive.^[1]
• The caution is driven by limited human data plus adverse animal reproductive findings — an unanswered safety question, which in pregnancy defaults to avoidance.^[1][2][3]
• Conceived on it? Stop, call your provider — don't panic. Harm is not established; the right move is prompt clinical guidance, not a solo decision.^[1][2]
• The Wegovy injection and the Wegovy tablet have DIFFERENT breastfeeding guidance. The tablet label advises against breastfeeding during treatment (due to the SNAC excipient); the injection label treats it as an individualized decision.^[1]
• Expect some weight regain during the washout. STEP-4 data show regain begins quickly after stopping semaglutide — plan the preconception window with that in mind, not around holding the on-drug number.^[8]
• "GLP-1 babies" reflect weight-loss-driven fertility gains and contraception slips — not a fertility drug. If you don't want to conceive, be more attentive to reliable birth control while on Wegovy.

If you are weighing whether and how to use Wegovy under proper medical supervision — including timing it around family planning — a legitimate provider will take a full history, discuss contraception and pregnancy intentions, and follow up. Compare the best semaglutide providers, or read our reviews of Found and Ro, and see the Wegovy and Ozempic drug pages for the full profile. Pregnancy and family-planning decisions belong with your OB-GYN or endocrinologist — this page is general education to bring to that conversation, not a substitute for it.